Schizophrenia, Bipolar, or Major Depressive Disorder and Postacute Sequelae of COVID-19

作者：Veer Vekaria, Rohith Kumar Thiruvalluru, Zoe Verzani, Sajjad Abedian, Mark Olfson, Braja Gopal Patra, Yunyu Xiao, Katherine S. Salamon, Karin F. Hoth, Frank Blanceró, Maxwell M. Hornig-Rohan, Teresa Akintonwa, Mahfuza Sabiha, Mark G. Weiner, Thomas W. Carton, Rainu Kaushal, Jyotishman Pathak, Selvin Soby, Parsa Mirhaji, Sara J. Deakyne Davies, Suchitra Rao, Priya Alekapatti, Nathan M. Pajor, Soumitra SenGupta, Curtis Kieler, W. Schuyler Jones, Nita Deshpande, Tony Pan, Carol R. Horowitz, Heidi T. May, Benjamin D. Horne, Bradley Taylor, Alexander J. Stoddard, Reza Shaker, David Liebovitz, V. F. Mitrović, Saul Blecker, Nathalia Ladino, Marion R. Sills, Soledad Fernández, Neena Thomas, Daniel Fort, Wenke Hwang, Cynthia H. Chuang, Alan R. Schroeder, Keith Morse, Sharon J. Herring, Yuriy Bisyuk, Mark J. Pletcher, Susan Kim, Mei Liu, Jiang Bian, Elizabeth A. Chrischilles, David A. Williams, Song Xing, Abu Saleh Mohammad Mosa, Jim Svoboda, Carol Geary, Michael J. Becich, Jonathan Arnold, Ramkiran Gouripeddi, Lindsay G. Cowell, Wei‐Qi Wei, Rainu Kaushal, Thomas R. Campion, Thomas W. Carton, Anna Legrand, Elizabeth Nauman, Mark G. Weiner, Sajjad Abedian, D. A. Brown, Christopher Cameron, Andrea Cohen, Marietou Dione, Rosie Ferris, Wilson Jacobs, Michael Koropsak, Alexandra LaMar, Colby Lewis, Dmitry Morozyuk, Peter Morrisey, Duncan Orlander, Jyotishman Pathak, Mahfuza Sabiha, Edward J. Schenck, Catherine Sinfield, Stephenson Strobel, Zoe Verzani, Fei Wang, Zhenxing Xu, Chengxi Zang, Yongkang Zhang · 发表于：JAMA Network Open · 年份：2025 · DOI：10.1001/jamanetworkopen.2025.40242 · 被引用次数：3 · 研究领域：Pharmacological Receptor Mechanisms and Effects、COVID-19 and Mental Health、Long-Term Effects of COVID-19

Importance: Given the increased vulnerability to COVID-19 among those with a serious mental illness (SMI), it remains unclear whether these individuals face a higher risk of developing postacute sequelae of SARS-CoV-2 (PASC). Understanding this association could inform secondary prevention efforts. Objective: To identify the risk of developing PASC in patients with an SMI. Design, Setting, and Participants: This longitudinal cohort study used data derived from large-scale electronic health records (EHRs) between March 2020 and April 2023, inclusive of 180-day follow-up. Patients included adults aged 21 years or older with a confirmed COVID-19 infection evidenced by a relevant laboratory result, diagnosis, or prescription order. Exposures: Evidence of an SMI diagnosis (schizophrenia, bipolar disorder, or recurrent major depressive disorder) recorded before COVID-19 infection. Main Outcomes and Measures: Evidence of PASC symptoms within 30 to 180 days' follow-up after COVID-19 infection reported as odds ratios (OR) mutually adjusted for age, sex, race and ethnicity, insurance type, Charlson Comorbidity Index (CCI) score, and COVID-19 severity. Results: A total of 1 625 857 patients with a COVID-19 infection were included (mean [SD] age, 52 [17] years; 998 237 [61.4%] female, 204 237 [12.6%] non-Hispanic Black, 219 220 [13.5%] Hispanic, 833 411 [51.3%] non-Hispanic White, and 1 228 664 [75.6%] urban patients), of whom 258 523 (15.9%) had an SMI and 403 641 (24.8%) developed PASC...